Difference between revisions of "MSK Biomarker Ctte"

From QIBA Wiki
Jump to: navigation, search
(Meetings)
(Meetings)
 
Line 9: Line 9:
  
 
'''Approved call summaries:'''
 
'''Approved call summaries:'''
 +
*[[Media:2021_03-23_QIBA_MSK_BC_Call_Summary-FINAL.pdf|March 23, 2021]]
 
*[[Media:2021_02-23_QIBA_MSK_BC_Call_Summary-FINAL.pdf|February 23, 2021]]
 
*[[Media:2021_02-23_QIBA_MSK_BC_Call_Summary-FINAL.pdf|February 23, 2021]]
 
*[[Media:2021_01-26_QIBA_MSK_BC_Call_Summary-FINAL.pdf|January 26, 2021]]
 
*[[Media:2021_01-26_QIBA_MSK_BC_Call_Summary-FINAL.pdf|January 26, 2021]]
*[[Media:2020_10-27_QIBA_MSK_BC_Call_Summary-FINAL.pdf|October 27, 2020]]
 
  
 
'''''[[MSK Biomarker Committee Call Summaries Archive]]'''''
 
'''''[[MSK Biomarker Committee Call Summaries Archive]]'''''

Latest revision as of 19:10, 27 April 2021

Co-chairs: Xiaojuan Li, PhD; Thomas M. Link, MD, PhD
RSNA Staff Support: Susan Stanfa

The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.

Meetings

Approved call summaries:

MSK Biomarker Committee Call Summaries Archive

Working Documents

  • QIBA MSK Profile 2020-01-28: MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease

Statistical Reference Documents

Workflow Documents

Reference Materials